Market News

Takeda Snaps up Nimbus’ Psoriasis Candidate for $4B

Healthcare major Takeda Pharmaceutical (NYSE:TAK) is acquiring clinical-stage company Nimbus Therapeutics’ subsidiary Nimbus Lakshmi and its product candidate NDI-034858.

The drug candidate is an oral, selective tyrosine kinase 2 (TYK2) inhibitor currently being evaluated for multiple autoimmune diseases post a successful Phase2b study in Psoriasis.

Importantly, Nimbus will receive $4 billion in an upfront cash payment and stands to receive a further $2 billion in commercial milestone payments under the deal.

The transaction is anticipated to be finalized in H1 2023. Takeda shares have now climbed 11% over the past month alone.

Read full Disclosure

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More